ELDN Stock Price, Eledon Pharmaceuticals, . Quote, Chart

Market Summary

USD3.04+0.24

Delayed

8.57%

ELDN Stock Price

View Fullscreen

ELDN RSI Chart

ELDN Valuation

Market Cap

117.1M

Price/Earnings (Trailing)

-2.94

Price/Sales (Trailing)

710.67

EV/EBITDA

-2.76

Price/Free Cashflow

-3.05

ELDN Price/Sales (Trailing)

ELDN Profitability

EBT Margin

-29651.47%

Return on Equity

-53.26%

Return on Assets

-49.31%

Free Cashflow Yield

-32.76%

ELDN Fundamentals

ELDN Revenue

Revenue (TTM)

136.0K

ELDN Earnings

Earnings (TTM)

-39.8M

Earnings Growth (Yr)

4.43%

Earnings Growth (Qtr)

-6.95%

Breaking Down ELDN Revenue

Last 7 days

31.6%

Last 30 days

93.6%

Last 90 days

66.1%

Trailing 12 Months

35.7%

How does ELDN drawdown profile look like?

ELDN Financial Health

Current Ratio

11.3

ELDN Investor Care

Shares Dilution (1Y)

71.09%

Diluted EPS (TTM)

-1.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2017	136.0K	0	0	0
2016	188.0K	212.0K	196.0K	164.0K
2015	168.0K	170.0K	172.0K	174.0K
2014	0	0	0	166.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Eledon Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 05, 2023	bvf partners l p/il	bought	-	-	1,978,930	-
Nov 23, 2022	perrin steven	bought	2,596	2.5969	1,000	president
Dec 20, 2021	gros david-alexandre c	bought	8,960	4.48	2,000	chief executive officer
Aug 17, 2021	gros david-alexandre c	bought	24,840	6.21	4,000	chief executive officer
Jun 11, 2021	little paul sean	bought	88,700	8.87	10,000	chief financial officer
Jun 09, 2021	gros david-alexandre c	bought	24,030	8.01	3,000	chief executive officer

Which funds bought or sold ELDN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	11,620	92,066	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-31.14	-8,851	32,923	-%
May 15, 2024	Royal Bank of Canada	reduced	-62.96	-	-	-%
May 15, 2024	BVF INC/IL	unchanged	-	1,124,940	8,913,020	0.24%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-39.32	-12,579	28,582	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-21,204	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	0.67	1,543	11,688	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	added	4.93	791,620	4,731,820	0.06%
May 15, 2024	Schonfeld Strategic Advisors LLC	new	-	104,648	104,648	-%
May 15, 2024	Woodline Partners LP	reduced	-5.43	102,182	1,342,990	0.01%

Are Funds Buying or Selling ELDN?

Are funds buying ELDN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ELDN

No. of Funds

Unveiling Eledon Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	biotechnology value fund l p	9.6%	2,330,418	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	0.00%	0	SC 13G/A
Feb 14, 2024	armistice capital, llc	9.99%	2,442,742	SC 13G
Feb 14, 2023	cormorant asset management, lp	9.99%	1,391,663	SC 13G/A
Feb 14, 2022	cormorant asset management, lp	9.90%	1,428,598	SC 13G/A
Feb 11, 2022	woodline partners lp	4.8%	685,273	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A

Recent SEC filings of Eledon Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 13, 2024	4	Insider Trading
May 07, 2024	8-K	Current Report
Apr 26, 2024	10-K/A	Annual Report
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Eledon Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Eledon Pharmaceuticals, Inc. News

Latest updates

Eledon Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q2	2014Q1
Revenue	13.0%	26,000	23,000	38,000	49,000	54,000	55,000	54,000	25,000	40,000	37,000	34,000	45,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.3%	81.00	89.00	96.00	107	82.00	93.00	150	155	161	171	177	184	192	197	193	11.00	14.00	11.00	15.00	18.00	13.00
Current Assets	-14.5%	48.00	56.00	63.00	74.00	49.00	60.00	68.00	73.00	79.00	88.00	96.00	103	110	116	115	10.00	13.00	10.00	12.00	15.00	10.00
Cash Equivalents	22.6%	6.00	5.00	4.00	41.00	47.00	56.00	66.00	70.00	77.00	85.00	94.00	101	109	114	114	9.00	12.00	9.00	11.00	14.00	14.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	-	-	-	-	-	-	-	49.00	49.00	49.00	49.00	49.00	49.00	49.00	49.00	44.00	-	-	-	2.00	2.00	2.00
Liabilities	6.2%	6.00	6.00	5.00	7.00	8.00	9.00	8.00	5.00	5.00	7.00	6.00	6.00	8.00	7.00	6.00	1.00	2.00	1.00	2.00	2.00	4.00
Current Liabilities	9.0%	4.00	4.00	3.00	5.00	5.00	6.00	6.00	3.00	3.00	4.00	4.00	3.00	4.00	2.00	6.00	1.00	2.00	1.00	2.00	2.00	3.00
Shareholder's Equity	-10.3%	75.00	83.00	91.00	100	75.00	84.00	141	149	156	164	171	179	184	191	22.00	9.00	12.00	9.00	13.00	16.00	10.00
Retained Earnings	-4.2%	-253	-243	-233	-223	-213	-202	-144	-134	-124	-114	-106	-96.30	-88.89	-80.39	-74.49	-68.34	-65.76	-57.58	-53.44	-50.54	-46.45
Additional Paid-In Capital	0.5%	328	327	325	323	288	287	286	283	281	279	277	275	273	271	96.00	78.00	77.00	67.00	67.00	67.00	56.00
Shares Outstanding	2.5%	25.00	24.00	24.00	23.00	14.00	14.00	14.00	14.00	14.00	14.00	15.00	15.00	15.00	15.00	-	-	-	-	-	-	-
Float	-	-	-	-	26.00	-	-	-	34.00	-	-	-	113	-	-	-	7.00	-	-	-	10.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	4.3%	-8,741	-9,131	-12,251	-8,221	-9,924	-9,480	-4,571	-6,217	-8,156	-9,208	-7,093	-7,446	-5,166	-9,433	-561	-3,021	-2,197	-2,023	-2,889	-4,922	-4,023
Share Based Compensation	-100.0%	-	1,710	1,734	1,720	1,381	1,474	2,185	2,308	2,186	2,053	2,043	2,034	1,774	1,659	878	197	437	243	227	627	211
Cashflow From Investing	-2.9%	9,783	10,076	-25,029	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	-	1.00	-	-	-	-	-	-	-	-	-	1.00	-	-450	9,164	95,226	-	5,191	-	-	9,569	107

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ELDN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 7,410	$ 8,113
General and administrative	3,459	2,997
Total operating expenses	10,869	11,110
Loss from operations	(10,869)	(11,110)
Other income, net	574	338
Net loss and comprehensive loss	$ (10,295)	$ (10,772)
Net loss per share, Basic	$ (0.34)	$ (0.75)
Net loss per share, Diluted	$ (0.34)	$ (0.75)
Weighted-average common shares outstanding, Basic	29,989,400	14,285,905
Weighted Average Number of Shares Outstanding, Diluted	29,989,400	14,285,905

ELDN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 5,655	$ 4,612
Short-term investments	37,207	46,490
Prepaid expenses and other current assets	5,115	5,027
Total current assets	47,977	56,129
Operating lease asset, net	270	365
In-process research and development	32,386	32,386
Other assets	185	186
Total assets	80,818	89,066
Current liabilities:
Accounts payable	1,864	967
Current operating lease liabilities	284	383
Accrued expenses and other liabilities	2,099	2,545
Total current liabilities	4,247	3,895
Deferred tax liabilities	1,752	1,752
Total liabilities	5,999	5,647
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock, $0.001 par value, 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 24,813,130 and 24,213,130 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	25	24
Additional paid-in capital	328,280	326,586
Accumulated deficit	(253,486)	(243,191)
Total stockholders’ equity	74,819	83,419
Total liabilities and stockholders’ equity	80,818	89,066
Series X1 Non-voting Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value
Series X Non-voting Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

CEO	Dr. David-Alexandre C. Gros M.D., Ph.D.
WEBSITE	https://eledon.com
INDUSTRY	Biotechnology
EMPLOYEES	17

Eledon Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Eledon Pharmaceuticals, Inc.? What does ELDN stand for in stocks?

ELDN is the stock ticker symbol of Eledon Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eledon Pharmaceuticals, Inc. (ELDN)?

As of Fri May 17 2024, market cap of Eledon Pharmaceuticals, Inc. is 117.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ELDN stock?

You can check ELDN's fair value in chart for subscribers.

What is the fair value of ELDN stock?

You can check ELDN's fair value in chart for subscribers. The fair value of Eledon Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Eledon Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ELDN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Eledon Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether ELDN is over valued or under valued. Whether Eledon Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Eledon Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ELDN.

What is Eledon Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ELDN's PE ratio (Price to Earnings) is -2.94 and Price to Sales (PS) ratio is 710.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ELDN PE ratio will change depending on the future growth rate expectations of investors.